• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Covidien, Medtronic shares jump on affirmation of $43B merger

Covidien, Medtronic shares jump on affirmation of $43B merger

October 22, 2014 By Brad Perriello

Covidien, Medtronic shares jump on affirmation of $43B merger

Shares of Medtronic (NYSE:MDT) and Covidien (NYSE:COV) both closed up yesterday after Medtronic affirmed its intention to consummate a $43 billion union with Covidien.

In a regulatory filing yesterday, Medtronic said it now expects the deal to close late in the 4th quarter or early in 2015. Investors reacted by sending COV shares up 4.5% to an $89.25 close yesterday; MDT shares closed up 1.8% at $64.98 each.

Medtronic also said that it’s board still supports the deal despite stricter U.S. Treasury rules on inversion deals, in which a U.S.-based company lowers its overall tax base by acquiring a foreign-based firm like Covidien, which is domiciled in Ireland but run from Mansfield, Mass. Medtronic responded by saying it would use external debt rather than the billions it has in offshore cash to finance the deal.

"In arriving at its determination on Oct. 2, 2014 to approve Medtronic’s use of external indebtedness to finance the cash component of the scheme consideration and to affirm its continued support of the transaction, the Medtronic board of directors consulted with Medtronic’s management, legal advisors and financial advisor, reviewed a significant amount of information, considered a number of factors in its deliberations and concluded that the transaction remained likely to result in significant strategic and financial benefits to Medtronic and its shareholders," according to the filing.

Investors yesterday were also likely encouraged by approval from Goldman Sachs and Perrella Weinberg of the new financing structure.

Medtronic also said it’s likely that Covidien will divest some businesses to satisfy U.S. anti-trust regulators (Japan, Russia, Israel and Turkey have already approved the merger, according to the filing). The divestitures could cost as much as $125 million in impairment charges, Medtronic said.

In a separate filing, Covidien president Bryan Hanson said he named Steve Blazejewski as president of the company’s medical supplies, respiratory & monitoring and venous solutions business. Hanson also named Chris Barry as president of Covidien’s surgical businesses.

Covidien said it also named members to a pair of new integration teams, an HR integration function group led by Covidien HR vice president Sandra McNeill and an organization, talent & culture team led by Kate Hoepfner-Karle, a member of both the integration management office and the leader of the new OTC team.

 

Filed Under: Mergers & Acquisitions, News Well, Respiratory, Wall Street Beat Tagged With: Covidien, Medtronic buys Covidien, Personnel Moves

More recent news

  • GE HealthCare expands digital imaging portfolio with enhanced MIM Encore software
  • Accelus wins FDA clearance for MRI compatibility of FlareHawk spinal implants
  • Presidio wins FDA IDE for ultra-low frequency neuromod, hires new CFO
  • Epiminder study backs implantable EEG tech
  • Neurent Medical wins FDA nod for next-gen chronic rhinitis treatment

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy